OBJECTIVES: Bipolar disorder (BD) is a psychiatric disease characterized by recurring mood episodes. One pharmacological treatment for BD is quetiapine fumarate, which exists in two formulations; extended release (XR) and immediate release (IR). The aim was to describe patient characteristics and treatment patterns for BD patients treated with quetiapine IR continuously vs. patients who were switched to XR. METHODS: BD patients with hospital admittance and prescription of quetiapine were identified from the Swedish National Patient Register and linked to the Prescribed Drug Register (ctw.gov, NCT01455961). Index date was defined as first prescription of quetiapine XR or first prescription of IR after 1 st January 2009. End of observation was 31 st December 2011. Data were analyzed by descriptive methods. RESULTS: A total of 5219 BD patients with prescriptions of XR/IR were identified. Of the 1761 patients using IR; 1303 patients later switched to XR, whereas 458 patients continuously used IR during the study period. Patients who later switched from IR to XR had more single depressions (47.1 vs. 40.4%) and anxiety disorders (36.1 vs. 30.3%), lower mean quetiapine IR dose (218 vs. 270 mg), and less medications for somatic diseases (39.0 vs. 46.5%), compared to patients continuing on IR. Following switch to XR, the number of concomitant medications (atypical antipsychotics and antidepressants) was reduced by 5.9 and 6.0%; while it increased by 3.0 and 0.7% in the IR continuous group, respectively. The quetiapine dose post-switch was higher in the group that switched to XR vs. the IR continuous group, 305 vs. 252 mg. CONCLUSIONS: Patients with bipolar disorder who switched to quetiapine XR had more psychiatric co-morbidity before switch compared to continuous IR patients. Following switch to XR, a higher mean quetiapine dose compared to the continuous IR group, and a decreased use of concomitant medications was found in this patient group.
PMH51 REAL WORLD ADD-ON AND SWITCH PATTERNS FOR DIFFERENT FORMULATION OF METHYLPHENIDATE
Håkan-Mose J, Löfroth E, Huetson P IMS Health, Stockholm, Sweden OBJECTIVES: To analyze the add-on and switch patterns for patients who dispensed different formulation of methylphenidate, in the South-West region of Sweden. METHODS: This was a retrospective database study of medication utilization amongst patients from the South-West region of Sweden (1.5 million inhabitants). All patients who dispensed Methylphenidate (ATC code: N06BA04), from 2006 to 2010 were included in the study. A dispatch was classified as new, switch, add-on, or continuation. All dispatches were annotated, at the drug type level, as either new (no other methylphenidate products within 90 days), add-on (another methylphenidate products dispatched both before and after), switch (another methylphenidate products dispatched before, but not after), or continuation (dispatched same drug type within 90 days). RESULTS: A total of 11731 patients had at least one methylphenidate filled prescription. The total number of dispatches for these patients were 219 750. 77% of all patients had been dispatched long acting methylphenidate, 44% modified release methylphenidate and 30% short acting methylphenidate. Long acting methylphenidate was dispatched as a new prescription in 19% of all dispatches, in Ͻ0.5% as add-on, 0.9% as switch, and in 80% as continuation. For modified release methylphenidate the distribution was 15% (new), 1% (add-on), 3% (switch), and 81% (continuation). For short acting methylphenidate the distribution was 10%, 10%, 8%, and 72%. CONCLUSIONS: Long acting methylphenidate is the most dispatched product type. Both long acting and modified release methylphenidate had first line treatment profiles, of which it was most pronounced for long acting methylphenidate (Ͻ1% add-on or switch). Short acting methylphenidate is used more as an add-on or switch therapy with 10% as add-on, 8% as switch, and only 10% as new dispatches. 
PMH52 HEALTH CARE RESOURCE UTILIZATION AND COSTS FOR PATIENTS WITH

OBJECTIVES:
The primary objective was to compare medical resource use and cost amongst patients diagnosed with anorexia nervosa (AN), bulimia nervosa (BN), and binge eating disorder (BED). METHODS: Eating disorders were identified retrospectively using IMS LifeLink claims data from January 2006 through June 2010. Eating disorder not otherwise specified (EDNOS) patients were subdivided into two groups: obese and non-obese. BED does not currently have a DSM-IV diagnosis, so obese subjects coded with EDNOS were used as a proxy for BED patients. Comorbidities, treatments, health care utilization, and costs were collected for 12 months before and after an eating disorder diagnosis. To compare outcomes in the follow-up period, Propensity Score Matching (PSM) was used to match each eating disorder cohort to a comparable control group based on pre-index demographic and clinical characteristics. RESULTS: Obese EDNOS patients had higher health care resource utilization than all other eating disorder groups. The biggest difference came from non-psychiatric related inpatient visits. Obese EDNOS patients (Nϭ4,534) had a total cost of $19,063 compared to $9,362 for the reference group (p-valueϽ0.001); non-obese EDNOS patients (Nϭ4,401) total cost was $10,022 vs. $5,444 for the controls (p-valueϽ0.001). AN patients (Nϭ1,942) had an average total cost of $14,961 versus $6,828 for the control patients (p-valueϽ0.001) while BN patients (Nϭ2,334) had an average total cost of $9,980 versus $5,840 for the controls (p-valueϽ0.001). CONCLUSIONS: Compared to matched control groups, health care costs were significantly greater for each eating disorder group. More frequent inpatient, outpatient, and outpatient ER visits characterized all three treatment groups. Overall, BED patients appear to have had the highest average annual cost of all cohorts.
